{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:17Z","timestamp":1786997897384,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011249","name":"Robert H Lurie Comprehensive Cancer Center of Northwestern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.urolonc.2025.09.020","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:46:48Z","timestamp":1761104808000},"page":"71.e19-71.e27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Should MRI-invisible low-risk prostate cancer be managed differently? A retrospective study of upgrading risk and future intervention"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6898-6785","authenticated-orcid":false,"given":"Jae Woong","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridwan","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Schnauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiten D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2025.09.020_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.020_bib0002","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 3.2024: featured updates to the NCCN guidelines","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compre Cancer Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.020_bib0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.020_bib0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.09.020_bib0005","first-page":"1547","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.020_bib0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of magnetic resonance imaging\u2013based active surveillance for prostate cancer: a large cohort study","volume":"78","author":"Stavrinides","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.020_bib0007","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bju.14513","article-title":"Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies","volume":"123","author":"Gallagher","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.020_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bju.13836","article-title":"Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer","volume":"120","author":"Alberts","year":"2017","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.020_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.12.036","article-title":"Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer","volume":"76","author":"Houlahan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.09.020_bib0010","first-page":"1","article-title":"Prognostic value of MR visibility\/invisibility in men on active surveillance","volume":"28","author":"Klotz","year":"2025","journal-title":"Prostate Canc Prost Dis"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.020_bib0011","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/JU.0000000000001157","article-title":"Does the visibility of grade group 1 prostate cancer on baseline multiparametric magnetic resonance imaging impact clinical outcomes?","volume":"204","author":"Deniffel","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.020_bib0012","first-page":"20","article-title":"Is confirmatory biopsy still necessary for active surveillance of men with grade group 1 prostate cancer in the era of multiparametric MRI?","volume":"213","author":"Bhanji","year":"2025","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.020_bib0013","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.020_bib0014","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","article-title":"Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis","volume":"78","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.09.020_bib0015","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000004498","article-title":"Negative predictive value of a prostate MRI in black men: implications for biopsy decision-making","author":"Sandlow","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.09.020_bib0016","first-page":"917","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020"},{"issue":"9","key":"10.1016\/j.urolonc.2025.09.020_bib0017","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamasurg.2019.1734","article-title":"Comparison of targeted vs systematic prostate biopsy in men who are biopsy naive: the prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) study","volume":"154","author":"Elkhoury","year":"2019","journal-title":"JAMA Surgery"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.020_bib0018","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.29874","article-title":"Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies","volume":"122","author":"Filson","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.020_bib0019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/JU.0000000000002120","article-title":"Systematic versus targeted Magnetic resonance imaging\/ultrasound fusion prostate biopsy among men with visible lesions","volume":"207","author":"Patel","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.020_bib0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41391-024-00911-2","article-title":"Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis","volume":"28","author":"Tay","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.020_bib0021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.16360","article-title":"The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer","volume":"134","author":"Rodriguez-Sanchez","year":"2024","journal-title":"BJU Int"},{"issue":"Suppl 4","key":"10.1016\/j.urolonc.2025.09.020_bib0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bju.16207","article-title":"Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy","volume":"133","author":"Geboers","year":"2024","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2025.09.020_bib0023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RLU.0000000000005724","article-title":"Using mpMRI, PSMA, and GRPR PET to assess focal therapy eligibility and plan treatment in biopsy-proven low-\/intermediate-risk prostate cancer: a whole-mount pathology-based study","volume":"50","author":"Li","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"3 Pt 1","key":"10.1016\/j.urolonc.2025.09.020_bib0024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.juro.2016.09.070","article-title":"Targeted biopsy to detect gleason score upgrading during active surveillance for men with low versus intermediate risk prostate cancer","volume":"197","author":"Nassiri","year":"2017","journal-title":"J Urol"},{"issue":"20","key":"10.1016\/j.urolonc.2025.09.020_bib0025","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.020_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/djae200","article-title":"Group C-GW. When is prostate cancer really cancer?","volume":"117","author":"Cooperberg","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.020_bib0027","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JU.0000000000001200","article-title":"Interreader Agreement with Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection: a systematic review and meta-analysis","volume":"204","author":"Park","year":"2020","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:37:57Z","timestamp":1773866277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1078143925003898"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should MRI-invisible low-risk prostate cancer be managed differently? A retrospective study of upgrading risk and future intervention","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}